Company Overview
Snapshot
Founded in April 1995, Nicast operates with 1–10 employees and has raised a total of $8.28 million across four funding rounds from three investors. The company received CE Mark approval for its vascular access graft in October 2008.
Business overview
Nicast specializes in developing implantable medical devices utilizing electrospun polymer nanofabrics. These nanofabric structures are engineered to mimic the body's extracellular matrix, facilitating tissue integration. The company applies this nanotechnology and biomaterials expertise to various medical applications, including its CE-certified AVflo polyurethane vascular access graft, designed to improve care for hemodialysis patients and reduce hospitalization. Nicast collaborates with medical device companies, research institutes, health authorities, and universities across Europe, Asia, and the U.S.
Strategic signal
In October 2008, Nicast secured CE Mark approval for its vascular access graft, a significant regulatory milestone that validated the device's compliance with European health, safety, and environmental protection standards. This approval was critical for market entry and adoption within the European medical device landscape, signaling the company's readiness to commercialize its innovative nanofabric technology for hemodialysis patients.
Log in to access full profile ›Company Intelligence Q&A
- What is Nicast's core technology?
- Nicast develops implantable medical devices using electrospun polymer nanofabrics, which are designed to mimic the body's extracellular matrix for enhanced tissue integration.
- When did Nicast receive CE Mark approval for its vascular access graft?
- In October 2008, Nicast received CE Mark approval for its vascular access graft, AVflo.
- Which investors participated in Nicast's October 2008 funding round?
- In October 2008, Nicast received funding from Azritech Ventures and Infinity Group.
- What is AVflo?
- AVflo is Nicast's CE-certified polyurethane vascular access graft, designed to provide a high-end solution for hemodialysis patients, improving patient care and reducing hospitalization time.